Global CRM197 Market Size By Type (Research Grade CRM197 and cGMP Grade CRM197), By Application (Meningococcal Polysaccharide Conjugate Vaccine, Pneumococcal Conjugate Vaccine), By Geographic Scope And Forecast

CRM197 Market Size And Forecast

CRM197 Market size was valued at USD 171.4 Million in 2021 and is projected to reach USD 277.51 Million by 2030, growing at a CAGR of 5.5% from 2023 to 2030.

CRM197 is supporting several crucial vaccinations that could play a key role in preventing deadly infections including meningitis and pneumonia. This, in turn, will boost market growth. The Global CRM197 Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global CRM197 Market Definition

So, CRM197? It's basically a workhorse now, acting as a carrier protein for polysaccharides. Think of it as making them stand out to your immune system, like putting them on a billboard. It's a modified version of diphtheria toxin, made to be non-toxic. But, and this is important, there's a big debate about just how non-toxic it really is. Some studies show it can be, well, poisonous to certain mammalian and yeast cells. Basically, it's a diphtheria toxin that's been genetically defanged. That single change, where they swapped out one amino acid (glycine) for another (glutamic acid) at spot 52, shuts down its nasty ADP-ribosyltransferase activity. Recently, scientists figured out exactly why this makes it safe. And because of all this, CRM197 is often used as a carrier protein in conjugate vaccines.

As CRM197 is genetically detoxified and retains its entire complement of lysine amines for conjugation, it may have an advantage over toxoided proteins. Additionally, there is evidence that suggests there is less carrier-induced immune response suppression as compared to tetanus toxoid, particularly when there are numerous different polysaccharides connected to the same carrier protein. There has been published a summary of CRM197’s features and usage. Similar to diphtheria toxin, CRM197 is a single, 535 amino acid, 58.4 kD polypeptide chain made up of two subunits (linked by disulfide bridges).

So, a lot of vaccines that help our bodies learn to fight off diseases use something called CRM197 as a carrier. Think of it like a tiny delivery truck for the important disease-fighting ingredients! The very first vaccine to use this CRM197 trick was HibtiterTM, which protects against Haemophilus influenzae type b, and it got the thumbs-up from the FDA back in 1990. Then came Pfizer's Prevnar, the first pneumococcal conjugate vaccine to be approved by the FDA; it contains sugary bits from different pneumococcal types, all attached to CRM197. Now, lots of new conjugate vaccines using CRM197 are being tested, both in labs and with people. For example, there's Menveo, a meningitis vaccine (ACWY) made by GlaxoSmithKline, that uses CRM197 too. And get thisMerck uses CRM197, made with something called the Pelican Expression Technology platform, in their VAXNEUVANCE vaccine, and the Serum Institute uses it in their Pneumosil vaccine as well!

Global CRM197 Market Overview

CRM197 is supporting several crucial vaccinations that could play a key role in preventing deadly infections including meningitis and pneumonia. As a result, this collaboration will aid in the development of affordable, essential vaccines, while FinaBio maintains the worldwide commercialization rights for EcoCRM, including exclusive rights outside of low-income nations and indications for non-infectious diseases.

Pneumococcal and meningococcal vaccines as well as several vaccines currently under development, such as those for Group B Streptococcus, Salmonella, Klebsiella, and malaria, frequently use CRM197, a genetically detoxified diphtheria toxin.

It is incorporated into Pfizer’s Prevnar 13, the most popular vaccination in the world and the only pneumococcal conjugate vaccine authorised in the US. In order to boost the immune response to the antigen, CRM197 is chemically joined (“conjugated”) to the antigen of interest as a component of these vaccines. One of the most intricate and pricey paediatric vaccinations available today is the conjugate vaccine.

Hundreds of millions of kids have been successfully immunised with vaccines that contain CRM197 as a carrier protein. A new tetravalent conjugate vaccine called Menveo, Menjugate and Meningitec (against serotype C of Neisseria meningitidis), Vaxem-Hib and HibTITER (against Haemophilus influenzae type B, Hib), and the multivalent pneumococcal conjugate Prevnar are examples of this type of vaccination.

Global CRM197 MarketSegmentation Analysis

The Global CRM197 Market is segmented based on Type, Application, And Geography.

CRM197 Market, By Type

• Research Grade CRM197• cGMP Grade CRM197

Based on Type, the market is segmented into Research Grade CRM197 and cGMP Grade CRM197.

CRM197 Market, By Application

• Pneumococcal Conjugate Vaccine• Meningococcal Polysaccharide Conjugate Vaccine• Others

Based on Application, the market is segmented into Meningococcal Polysaccharide Conjugate Vaccine, Pneumococcal Conjugate Vaccine, and others.

CRM197 Market, By Geography

• North America• Europe• The Asia Pacific• Rest of the world

Based on regional analysis, the Global CRM197 Market is classified into North America, Europe, Asia Pacific, and the Rest of the world.

Key Players

The major players in the Global “CRM197 Market” are Pfizer Inc., Fina Biosolutions, Eubiologics, EirGenix Inc., Xpress Biologics, and Ligand Pharmaceuticals. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• August 2020Pfenex and Merck signed a research and collaboration agreement to evaluate a specified set of proteins to be produced through the Pfenex Expression Technology platform. Under the terms of the arrangement, Pfenex will receive an upfront payment in the amount of $2.5 million dollars and research funding.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We'll dig into the market with a mix of both qualitative (thinkfeelings, reasons) and quantitative (thinknumbers, hard data) analysis. We'll break it all down by segmentation, considering all sorts of things that influence buyers. You'll get the scoop on market value in good ol' USD Billion for every area we look at. We'll even point out which region and segment we think will be the rock stars, experiencing the most growth and taking over the market. Get ready for a region-by-region breakdown, highlighting how much of the product/service is being gobbled up and what's making each area tick. Want to know who the big dogs are? We'll lay out the competitive scene, ranking the major players and flagging any new product launches, partnerships, expansions, or acquisitions from the last five years. Plus, we've got detailed company profiles, giving you the inside scoop on each company with overviews, insights, product comparisons, and SWOT analyses. We'll also paint a picture of where the market is now and where it's headed, considering recent happenings, growth opportunities, and the challenges holding things back in both up-and-coming and established regions. And to really dig deep, we'll analyze the market from all angles using Porter's Five Forces. Plus, you’ll get a feel for the Value Chain. We'll serve up market dynamics, growth opportunities, and, to top it all off, 6 months of analyst support after the sale to help you navigate it all.

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.